ABSTRACT
Importance Quantitative, sensitive and operator-independent biomarkers of disease progression are needed to minimize the size, duration, and cost of clinical trials in amyotrophic lateral sclerosis (ALS) to allow a more effective investigation of promising therapeutic agents.
Objective We assess the potential of skeletal muscle magnetic resonance imaging (MRI) as a sensitive and reliable outcome measure for future ALS clinical trials.
Design In this longitudinal cohort study, muscle MRI of head-neck, upper, and lower limb regions, along with clinical and functional assessments, were acquired at three timepoints over the individual maximum observation period (iMOP) of 1 year.
Participants Twenty consecutive ALS patients were recruited from a motor neuron disease clinic between 2015 and 2017, along with 16 healthy controls.
Main outcomes and measures Quantitative MRI parameters CSA (cross-sectional area), VOL (muscle volume), FF (fat fraction), functional rest muscle area (fRMA) and water T2 (T2m) were used to assess progressive muscle degeneration and were correlated with changes in clinical parameters of disease severity (functional rating scales and myometry). Standardized response mean (SRM) was calculated for MRI outcome measures.
Results Out of 20 ALS patients, 17 were available for follow-up. A significant decline in VOL of the dominant hand (rs=0.66, p<0.001) and head and neck muscles (partial η²=0.47, p=0.002) as well as CSA of the lower limbs (thighs: partial η²=0.56, p<0.001, calves: partial η²=0.54, p<0.001) was observed over iMOP, with highest responsiveness for progressive atrophy in hand (SRM -1.17) and leg muscles (thigh: SRM -1.09; calf: SRM -1.08). Furthermore, lower limb FF and T2m increased over time, with distal leg muscles being most affected (FF: partial η²=0.54, p=0.002, SRM 0.81; T2m: partial η²=0.37, p=0.01, SRM 0.74). Finally, longitudinal MRI changes showed correlation with strength in leg muscles (knee extension: r=0.77, p=0.001, 95% CI 0.46–0.91; plantar flexion: r=0.78, p<0.001, 95% CI 0.47 – 0.92), and fRMA decrease at thigh and calf level correlated with global clinical disease progression measured with ALSFRS (r=0.52, p=0.03, and r=0.68, p=0.004 respectively).
Conclusions and Relevance Our findings demonstrate the effectiveness of muscle MRI as a sensitive neuroimaging biomarker of disease progression in ALS, highlighting its potential application in clinical trials.
Key Points Question: Can quantitative muscle MRI track disease progression over time in patients with amyotrophic lateral sclerosis (ALS)?
Findings: Longitudinal quantitative MRI reliably detects progressive intramuscular fat infiltration, oedema and atrophy, which correlate with progressive loss of muscle strength.
Meaning: Muscle MRI has the potential to be utilised as a biomarker for ALS disease progression and could contribute to reduce the size and duration of clinical trials facilitating future drug developments.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the UCLH NIHR Biomedical Research Centre. UK is funded by KD-UK. PF is funded by an MRC and MNDA LEW Fellowship. LG is the Graham Watts Senior Research Fellow funded by the Brain Research Trust.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UCL Research Ethics Committee gave ethical approval for this work (11/LO/1425) and written informed consent was obtained from all participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data available: No. Additional Information: Explanation for why data not available: The data that support the findings of this study are controlled by the respective centers and are not publicly available. Request to access the raw data should be forwarded to data controllers via the corresponding author. Written requests for access to the derived data will be considered by the corresponding author and a decision made about the appropriateness of the use of the data.
